Metabolism News and Research

Latest Metabolism News and Research

Researchers use hydrogels to induce significant vasculature growth in areas of damaged tissue

Regenerative medicine therapies often require the growth of functional, stable blood vessels at the site of an injury. Using synthetic polymers called hydrogels, researchers at the Georgia Institute of Technology have been able to induce significant vasculature growth in areas of damaged tissue.

22 Dec 2009

Investigation of IDH1 gene mutations in brain cancer receives new funds

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2’s funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios’s ongoing research into the development of new IDH1 therapeutics and diagnostics.

21 Dec 2009

Pico-Tesla commences enrollment in its Magneceutical therapy study for type 2 diabetes

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has enrolled the first seven patients for a randomized, double-blind, placebo-controlled Pilot Study of persons who have type 2 diabetes, the most common form of diabetes. The Pilot Study seeks to determine whether the application of magnetic fields generated by the Company’s patented Resonator™ system can be effective as an adjunctive therapy to oral medications in reducing hemoglobin A1c levels.

18 Dec 2009

JDRF to work with Johnson & Johnson to develop drug targets and pathways for treating diabetes

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes.

18 Dec 2009

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.

18 Dec 2009

Roche Diagnostics and Takara Bio enter into license agreement

Roche Diagnostics and Takara Bio, the Shiga (Japan)-based supplier of systems for use in life science research, announced that they have entered into a license agreement for use of the melting curve analysis technology and SYBR Green techniques in their Kits and Instruments for Real Time PCR.

From Roche Sequencing and Life Science 18 Dec 2009

Diet rich in omega-3 fatty acids linked to improved nervous-system function

The omega-3 essential fatty acids commonly found in fatty fish and algae help animals avoid sensory overload, according to research published by the American Psychological Association.

17 Dec 2009

UC San Diego Medical Center performs complex surgery on brain lesion

Over three decades, a world-recognized medical team at UC San Diego Medical Center has spurred the evolution of a complex surgery to destroy dangerous clusters of arteries and veins in the brain. Integrating innovative approaches in radiology, anesthesia, and surgery, the team has perfected a method to systematically starve these abnormal brain lesions, artery by artery, vein by vein.

17 Dec 2009

Arizona State University and Mayo Clinic team up to explore metabolic syndrome

Arizona State University and Mayo Clinic in Arizona are joining forces in a partnership to investigate metabolic syndrome - a cluster of high-risk medical factors that include increased blood pressure, elevated insulin levels, excess body fat and abnormal cholesterol levels, which can lead to heart disease, stroke and diabetes.

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Studies reveal new benefits of Peptan in preventing osteoporosis

Studies Conducted at INRA-Agroparistech Laboratory Under Pr. Daniel Tome's Supervision and Published in November 2009, in the Official Journal of the International Bone and Mineral Society "Bone", Reveal new Benefits for Peptan(TM) in Osteoporosis Prevention

16 Dec 2009

imaGenes achieves Roche NimbleGen CSP-status for ChIP-chip application

Roche NimbleGen has announced that imaGenes GmbH, a Berlin-based genomics & proteomics specialist, has achieved status as a Certified Service Provider (CSP) of NimbleGen microarrays for Chromatin Immunoprecipitation (ChIP-chip). imaGenes GmbH has passed a rigorous ChIP-chip certification to officially become part of the Roche NimbleGen Certified Service Provider Program.

16 Dec 2009

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

SRI International, an independent nonprofit research and development organization, announced today the award of U.S. patent 7,592,021 for a new bioadhesive drug delivery system that enables enhanced release of drugs through the human body's mucous membranes.

16 Dec 2009

NovaDel receives Issue Notification from USPTO for oral spray

NovaDel Pharma Inc., today announced that it received an Issue Notification from the United States Patent and Trademark Office (USPTO) for a new U.S. Patent, No. 7632517, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaDel’s oral spray technology.

16 Dec 2009

Positive results from study comparing exenatide once weekly to BYETTA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes.

15 Dec 2009

Bend Research makes available Type V DMF for HPMCAS concerning FDA regulatory filings

Bend Research Inc. announced today that its clients may now reference a key safety file for HPMCAS, an excipient used in technologies developed by the firm to enhance the oral bioavailability of clients' low-solubility drugs.

15 Dec 2009

Over three hundred proteins investigated to understand the mechanism that allows limbs to regenerate

The most comprehensive study to date of the proteins in a species of salamander that can regrow appendages may provide important clues to how similar regeneration could be induced in humans.

15 Dec 2009

Findings suggest variations in accelerated aging disorders

UT Southwestern Medical Center researchers have provided the most extensive account to date of the unique observable characteristics seen in patients with an extremely rare premature aging syndrome.

15 Dec 2009

Study to determine link between insulin glargine and cancer

Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications. However, these studies were unable to control for important factors such as obesity that may have driven the association.

15 Dec 2009

CureDM receives patent allowance for novel islet neogenesis program

CureDM, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering a Human proIslet Peptide (HIP) and methods related to its use and administration for treating type 1 diabetes.

15 Dec 2009

Metabolism News and Research

Latest Metabolism News and Research

Researchers use hydrogels to induce significant vasculature growth in areas of damaged tissue

Investigation of IDH1 gene mutations in brain cancer receives new funds

Pico-Tesla commences enrollment in its Magneceutical therapy study for type 2 diabetes

JDRF to work with Johnson & Johnson to develop drug targets and pathways for treating diabetes

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Roche Diagnostics and Takara Bio enter into license agreement

Diet rich in omega-3 fatty acids linked to improved nervous-system function

UC San Diego Medical Center performs complex surgery on brain lesion

Arizona State University and Mayo Clinic team up to explore metabolic syndrome

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Studies reveal new benefits of Peptan in preventing osteoporosis

imaGenes achieves Roche NimbleGen CSP-status for ChIP-chip application

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

NovaDel receives Issue Notification from USPTO for oral spray

Positive results from study comparing exenatide once weekly to BYETTA

Bend Research makes available Type V DMF for HPMCAS concerning FDA regulatory filings

Over three hundred proteins investigated to understand the mechanism that allows limbs to regenerate

Findings suggest variations in accelerated aging disorders

Study to determine link between insulin glargine and cancer

CureDM receives patent allowance for novel islet neogenesis program

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves